Crescent Grove Advisors LLC Has $6.23 Million Stake in iShares Biotechnology ETF (NASDAQ:IBB)

Crescent Grove Advisors LLC lowered its position in iShares Biotechnology ETF (NASDAQ:IBB) by 1.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 42,800 shares of the financial services provider’s stock after selling 749 shares during the period. Crescent Grove Advisors LLC owned 0.08% of iShares Biotechnology ETF worth $6,232,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC bought a new position in shares of iShares Biotechnology ETF in the 3rd quarter valued at approximately $30,000. Bbjs Financial Advisors LLC acquired a new position in iShares Biotechnology ETF in the 2nd quarter valued at approximately $31,000. Voisard Asset Management Group Inc. acquired a new position in shares of iShares Biotechnology ETF in the third quarter valued at $59,000. Eastern Bank acquired a new position in shares of iShares Biotechnology ETF in the 3rd quarter valued at $65,000. Finally, Chris Bulman Inc bought a new position in iShares Biotechnology ETF during the second quarter worth about $64,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Up 1.5 %

Shares of IBB stock opened at $145.06 on Wednesday. The stock’s fifty day simple moving average is $144.86 and its 200 day simple moving average is $140.84. iShares Biotechnology ETF has a one year low of $113.56 and a one year high of $150.57.

iShares Biotechnology ETF Dividend Announcement

The company also recently announced a dividend, which was paid on Monday, September 30th. Investors of record on Wednesday, September 25th were given a dividend of $0.2005 per share. The ex-dividend date was Wednesday, September 25th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.